Novan Stock Forecast, Price & News

+0.07 (+0.67 %)
(As of 06/24/2021 01:45 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume10,630 shs
Average Volume2.90 million shs
Market Capitalization$160.21 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter.

Novan logo

About Novan

Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Morrisville, North Carolina.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.22 out of 5 stars

Medical Sector

952nd out of 2,105 stocks

Pharmaceutical Preparations Industry

465th out of 832 stocks

Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Novan (NASDAQ:NOVN) Frequently Asked Questions

Is Novan a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Novan stock.
View analyst ratings for Novan
or view top-rated stocks.

What stocks does MarketBeat like better than Novan?

Wall Street analysts have given Novan a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novan wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Novan?

Novan saw a drop in short interest during the month of May. As of May 28th, there was short interest totaling 306,500 shares, a drop of 87.5% from the May 13th total of 2,460,000 shares. Based on an average trading volume of 634,800 shares, the days-to-cover ratio is currently 0.5 days. Currently, 2.1% of the company's shares are short sold.
View Novan's Short Interest

When is Novan's next earnings date?

Novan is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Novan

How were Novan's earnings last quarter?

Novan, Inc. (NASDAQ:NOVN) issued its earnings results on Tuesday, May, 11th. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The firm had revenue of $0.82 million for the quarter, compared to the consensus estimate of $0.96 million. Novan had a negative net margin of 708.75% and a negative trailing twelve-month return on equity of 1,050.18%.
View Novan's earnings history

How has Novan's stock price been impacted by Coronavirus?

Novan's stock was trading at $0.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NOVN stock has increased by 1,930.8% and is now trading at $10.56.
View which stocks have been most impacted by COVID-19

What price target have analysts set for NOVN?

2 Wall Street analysts have issued 12 month target prices for Novan's shares. Their forecasts range from $2.00 to $3.00. On average, they expect Novan's share price to reach $2.50 in the next year. This suggests that the stock has a possible downside of 76.3%.
View analysts' price targets for Novan
or view top-rated stocks among Wall Street analysts.

Who are Novan's key executives?

Novan's management team includes the following people:
  • Ms. Paula Brown Stafford, Pres, CEO & Chairwoman (Age 56, Pay $897.86k)
  • Mr. John M. Gay, CFO & Corp. Sec. (Age 44, Pay $408.03k)
  • Mr. Andrew J. Novak, VP of Accounting & Bus. Operations and Chief Accounting Officer
  • Dr. Carri Geer, Sr. VP & CTO
  • Mr. Cole Ikkala, Director of Investor Relations, Communications & Bus. Devel.
  • Mr. Stanley Hollenbach BS, J.D., Sr. VP of R&D
  • Ms. Elizabeth Messersmith, Sr. VP & Chief Devel. Officer

Who are some of Novan's key competitors?

What other stocks do shareholders of Novan own?

When did Novan IPO?

(NOVN) raised $46 million in an initial public offering on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

Who are Novan's major shareholders?

Novan's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.76%), Renaissance Technologies LLC (1.20%), Geode Capital Management LLC (0.78%), Millennium Management LLC (0.73%), Northern Trust Corp (0.20%) and Morgan Stanley (0.17%). Company insiders that own Novan stock include Life Sciences Holdings L Malin and Paula B Stafford.
View institutional ownership trends for Novan

Which major investors are selling Novan stock?

NOVN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for Novan
or view top insider-selling stocks.

Which major investors are buying Novan stock?

NOVN stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, Citadel Advisors LLC, Geode Capital Management LLC, Squarepoint Ops LLC, Edmond DE Rothschild Holding S.A., Price T Rowe Associates Inc. MD, and Bank of New York Mellon Corp.
View insider buying and selling activity for Novan
or or view top insider-buying stocks.

How do I buy shares of Novan?

Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novan's stock price today?

One share of NOVN stock can currently be purchased for approximately $10.56.

How much money does Novan make?

Novan has a market capitalization of $160.21 million and generates $4.92 million in revenue each year. The company earns $-29,290,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

How many employees does Novan have?

Novan employs 23 workers across the globe.

What is Novan's official website?

The official website for Novan is

Where are Novan's headquarters?

Novan is headquartered at 4105 HOPSON ROAD, MORRISVILLE NC, 27560.

How can I contact Novan?

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at (919) 485-8080 or via email at [email protected]

This page was last updated on 6/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.